Abstract-Zomepirac sodium inhibited the reflex hypertension caused by an injection of bradykinin into the splenic artery of anaesthetized dogs, but not that by injection of bradykinin plus PGE1. In the rat acetic acid writhing test, the potency ratio of intra peritoneal (ED50=0.41 itg/kg) to intravenous (ED50=33.5 ,ug/kg) anti-writhing activity of zomepirac sodium was 79.2 (37.1-173), though the ratio of codeine phosphate (373 ,ug/kg, i.p., 352 ig/kg, i.v.) was 0.934. When equipotent doses of zomepirac sodium were administered to rats receiving intraperitoneally acetic acid, the plasma zomepirac level after i.v. administration was more than 200 times that after i.p. adminis tration, while the peritoneal exudate zomepirac contents were nearly equal after adminis tration by both routes. Zomepirac sodium (5 ug/kg) did not produce significant anti writhing activity after intracerebroventricular administration. From these results, it was suggested that zomepirac sodium produced analgesic action through a strong blockade of the hyperalgesia in the peripheral system.
Zomepirac sodium, sodium 5-(4-chloro benzyol)-1,4-dimethyl-1 H-pyrrole-2-acetate dehydrate, is a non-narcotic analgesic that is chemically related to tolmetin sodium, a non-steroidal anti-inflammatory drug. Pruss et al. (1) have reported that the anti-writhing activity of orally administered zomepirac sodium was approx. equal to that of subcutaneously administered morphine and superior to that of aspirin and codeine in the acetylcholine writhing test, but it is not effective in the Haffner and hot plate tests in mice which readily detect codeine. In clinical trials, zomepirac sodium has been reported to produce a potent analgesic activity that is equipotent to or superior to that of aspirin and narcotic analgesics such as morphine, pentazocine and APC (aspirin, phenacetin and caffeine) plus codeine (2) (3) (4) (5) (6) . Zomepirac sodium, however, has been shown to be a potent inhibitor of prostaglandin synthetase, approx. equivalent to indomethacin in potency (1) and to have a potent anti inflammatory activity (7) . It is interesting that zomepirac sodium is comparable to some narcotic analgesics in potency in man, in spite of its similarity to non-steroidal anti inflammatory drugs. Thus, this investigation was designed to ascertain whether the site for the analgesic action of zomepirac sodium is different from that of other non-steroidal anti-inflammatory drugs.
Materials and Methods
Drug: Sodium 5-(4-chlorobenzoyl) -1,4 dimethyl-1 H-pyrrole-2-acetate dehydrate (zomepirac sodium), codeine phosphate and morphine hydrochloride were used. Drugs were dissolved in saline for intravenous and intraperitoneal administration and dissolved in 0.5% gum tragacanth aqueous solution for oral administration. Dosages were ex pressed as the salt form of the drug. In all experiments, zomepirac sodium was adminis tered as the sodium salt dihydrate; 100 mg zomepirac sodium is equivalent to 83.33 mg zomepirac. Bradykinin evoked visceral pain: Mongrel dogs weighing 8 to 1 2 kg were anaesthetized with hexobarbital sodium (30 mg/kg, i.v.) and a-chloralose (30-50 mg/kg, i.v.). Under anaesthesia, a branch of the splenic artery and cephalic vein were cannulated with polyethylene tubes for bradykinin and drug injection, respectively. The femoral artery was also cannulated for measuring blood pressure. After waiting 2 hr or more, a starting dose of 1 tg of bradykinin (Protein Research Foun dation, Osaka) was injected intraarterially into the spleen through the cannulae assembly under light anaesthesia, and only animals showing an increase in blood pressure (hypertension) by bradykinin was measured before and 5, 1 5 and 30 min after intravenous administration of the test drug (8-10).
Anti-writhing test: Male Wistar rats weighing 100 to 110 g were used in the acetic acid writhing test. Each rat was given intraperitoneally 1 ml of a 1 % acetic acid aqueous solution and was settled into a cylindrical cage (24.5 cm in diameter) made of transparent acrylic resin. Only the rats showing a writhing syndrome within 15 min after acetic acid injection were used for the experiment. Drugs were administered to the rats 60 min after acetic acid injection, and then the number of writhes was counted for 20 min (11, 12).
Female ddN mice weighing 18 to 22 g were used in the phenylquinone writhing test. Each mouse was given intraperitoneally 0.1 ml/10 g body weight of a 0.03% phenyl quinone solution in 5% aqueous ethanol, and the number of writhes was counted for 1 5 min beginning from 5 min after phenylquinone injection. Drugs were administered orally 30 min before phenylquinone injection (13, 14) .
A reduction in writhing counts greater than 50% of the vehicle control value was considered to be significant (effective). The anti-writhing ED50-value was calculated from the effective rates (percentages of number of animals effective/tested) according to the method of Litchfield and Wilcoxon (15) . Intracerebroventricular injection: Male Wistar rats weighing 100 to 110 g were used.
A guide cannula was stereotactically im planted into the lateral ventricle of the brain under hexobarbital sodium anaesthesia, and 5 days later, the rats were used for the acetic acid-induced writhing test. After intra cerebroventricular (i.c.v.) administration of test drugs, the injected site was confirmed by injecting Evan's blue dye in the same manner.
Determination of zomepirac sodium in plasma and peritoneal exudate: The blood was obtained by heart puncture from the rat receiving intraperitoneally acetic acid under ether anaesthesia, and then after death, the exudate in the peritoneal cavity was washed out with 10 ml of distilled water. Zomepirac in plasma and the exudate was extracted and determined according to the method of Kojima and Yoshida in our laboratories as follows: A half ml of plasma was put in a cen trifuge tube (15 ml vol.), acidified with 3 ml of 6 N H2SO4, shaken with 5 ml of n-heptane containing 1.5% isoamylalcohol for 15 min, and then centrifuged at 2,200 rpm for 10 min. Four ml of the n-heptane layer was evaporated by bubbling with air in a water bath at 50°C. The residue was dissolved in 0.1 ml of methanol, and 10 to 20 i l of the methanol solution was injected into the column of a high-performance liquid chromatograph (HPLC). The peritoneal exudate with wash ings was pooled, and 5 ml of this was ex
tracted by the same procedure as used for the plasma. A Waters Model 204-chromatograph and ,a-Bondapack NH2 column were used with a Model 6000A Solvent Delivery System, Model U6K Universal Injector and Model UV440 Absorbance Detector. The eluent constituent consisted of a mixture of 1 % acetic acid, methanol and acetonitrile (1/1/5 by vol.). The flow rate was 2.5 ml/min and the effluent was monitored at 254 nm. Retention time of zomepirac is 3.8 min. A known amount of zomepirac sodium was added to the pooled plasma and the pooled exudate from the rat receiving an intra peritoneal injection of acetic acid, and the calibration curve was estimated. Zomepirac contents in the sample were determined from the calibration curve.
Statistics: The potency ratio was deter mined according to the method of Finney (16), and statistical significance was deter mined by Student's t-test.
Results
Tolerance and naloxone antagonism of anti-writhing action: The anti-writhing ED50 value of zomepirac sodium has been reported to be 0.91 mg/kg given orally in the mouse phenylquinone writhing test (17) . Thus, 5 mg/kg of zomepirac sodium was given orally to the mice once a day for 7 days; and on the 8th day, the anti-writhing activity of zomepirac sodium was compared with that in the mice repeatedly given the vehicle in the phenylquinone writhing test. The anti writhing ED50-values (95% confidence limits) of both groups were the same: 0.982 (0.191-5.06) mg/kg, p.o. Thus, analgesic tolerance to zomepirac sodium was not produced. Under the same experimental conditions, tolerance to codeine phosphate has been found to be produced (18).
Anti-writhing activity (inhibitory rate= 70.0%, n=7) of zomepirac sodium (3 nmig/kg, PGE, was approx. equivalent to 1 og/ dog of bradykinin. When bradykinin or bradykinin plus PGE, was given intraarterially to the dog 3 to 5 times at 10 min intervals, constant pressure responses were found to he evoked. When zomepirac sodium was given intra venously to the dog at doses of 4 to 16 mg/ kg, the hypertension by bradykinin was inhibited in a dose-dependent manner. Eight mg/kg, i.v., of zomepirac sodium produced the maximum reduction of 60.4±15.5% (n=4) (among three determinations as compared with the pre-drug value) of the hypertension by bradykinin, but only 18.6±6.5% (n=4) of that by bradykinin plus PGE, (Fig. 1) Drugs were administered intraperitoneally or intravenously to the rat 60 min after acetic acid injection, and then the number of writhes was counted for 20 min. The ED50-value was calculated from the effective rates (See Fig. 2 explanation) . *0.01<P<0.05 and **P<0.01, significantly different from each saline control. n: number of rats used. Fig. 2 . Comparison of anti-writhing activities of zomepirac sodium and codeine phosphate by intraperi toneal and intravenous administration in rats. Each drug was administered intraperitoneally (open symbols, broken lines) and intravenously (closed symbols, solid lines) to the rat. When the rat showed half or less of the number of writhes counted in the vehicle control group, the dose was considered to be effective. The ordinate scale represents the percentages of number of rats in which the dose was effective/ number of rats tested. Table 2 . Exudate and plasma zomepirac levels after intraperitoneal or intravenous administration of zomepirac sodium in rats Zomepirac sodium was administered intraperitoneally or intravenously to the rat 60 min after acetic acid injection; and 5 min later, zomepirac contents in the peritoneal exudate and plasma were determined. 80 times more potent than that after intra venous administration. In contrast, ED50 values of codeine phosphate were 373 ag/ kg, i.p., and 352 ug/kg, i.v. (Table I) , and the potency ratio of codeine phosphate was 0.934 (0.398-1.95), n=42.
Zomepirac levels in plasma and peritoneal exudate: Four and 160 ag/kg of zomepirac sodium were administered intraperitoneally and intravenously, respectively, to the rat 60 min after acetic acid injection; and 5 min later, zomepirac levels in the plasma and peritoneal exudate were determined. As shown in Table 2 Table 3 . Anti-writhing activity of zomepirac sodium and morphine hydrochloride after intra cerebroventricular administration in rats Drugs were administered intracerebroventricularly (i.c.v.) to the rat 60 min after acetic acid injection, and then the number of writhes was counted for 20 min. **P<0.01, significantly different from the saline control. °) : pl/kd, i.c.v. through the guide cannulae implanted pre viously. Then, the number of writhes was counted for 20 min after zomepirac sodium administration.
Zomepirac sodium did not produce significant anti-writhing activity after i.c.v. administration of 5 dig/kg. In contrast, morphine hydrochloride showed a potent anti-writhing activity after a single adminis tration of 5 /,,g/kg, i.c.v., and its inhibitory rate was 80.9% (P<(0.01) ( anti-writhing activity of zomepirac sodium after intraperitoneal administration was about 80 times more potent than that after intra venous administration, and also there was a correlation between the anti-writhing activity and the zomepirac contents in the peritoneal exudate. Thus, it is suggested that site for the anti-writhing action of zomepirac sodium, unlike codeine and morphine, is mostly in the peritoneum (peripheral system).
A significant anti-writhing action was not found when zomepirac sodium was admin istered intracerebroventricularly at 5 /-,g/kg (about 10 times of the i.p. ED50). The slight inhibitory action of zomepirac sodium might be due to a direct action of zomepirac sodium on the central nervous system and/or an action of zomepirac sodium which had leaked out into blood from the cerebroven tricule, or it might be due to a non-specific action of zomepirac sodium. This lack of analgesic action by zomepirac sodium is in accord with the data of Capetola et al. (23) who showed that zomepirac sodium (total doses of 25 and 50 /ig), but not morphine sulfate (10 /cg), failed to cause significant analgesic effects after direct injection into the lateral ventricle in the rat adjuvant arthritic flexion assay. It has been reported that the brain zomepirac level (0.48 iig/g) is 2.08% of the plasma level (23.1 /cg/ml) 6 hr after a single oral administration of 6 mg/kg of zomepirac, and the peak time in the plasma level is about 4 hr after dosing (24). This brain level is lower than the other organs tested: one-third and one-ninth that in the muscle and skin, respectively.
Thus, it is improbable that zomepirac accumulates highly in the brain after intravenous or intra 
